Brexpiprazole has a low risk of dopamine D 2 receptor sensitization and inhibits rebound phenomena related to D 2 and serotonin 5‐HT 2A receptors in rats-Reference-Cited by-同舟云学术

Brexpiprazole has a low risk of dopamine D 2 receptor sensitization and inhibits rebound phenomena related to D 2 and serotonin 5‐HT 2A receptors in rats

Published:2019-09-05 Issue:4 Volume:39 Page:279-288
ISSN:2574-173X
Container-title:Neuropsychopharmacology Reports
language:en
Short-container-title:Neuropsychopharmacol Rep

Author:

Amada Naoki¹^ORCID,Akazawa Hitomi¹,Ohgi Yuta¹,Maeda Kenji²,Sugino Haruhiko³,Kurahashi Nobuyuki⁴,Kikuchi Tetsuro⁵,Futamura Takashi¹

Affiliation:

1. Department of CNS Research Otsuka Pharmaceutical Co., Ltd. Tokushima Japan

2. Department of Lead Discovery Research Otsuka Pharmaceutical Co., Ltd. Tokushima Japan

3. Global Business Development Otsuka Pharmaceutical Development and Commercialization, Ltd. Princeton New Jersey

4. Global CNS Business Otsuka Pharmaceutical Development and Commercialization, Ltd. Princeton New Jersey

5. Pharmaceutical Division Otsuka Pharmaceutical Co., Ltd. Tokushima Japan

Funder

Otsuka Pharmaceutical

Publisher

Wiley

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology,Clinical Psychology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/npr2.12076

Reference63 articles.

1. Rethinking schizophrenia

2. Catching Up on Schizophrenia

3. Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence

4. The Role of Serotonin in Antipsychotic Drug Action

5. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brexpiprazole: A new option in treating agitation in Alzheimer's dementia—Insights from transgenic mouse models;Neuropsychopharmacology Reports;2024-06-25

2. Brexpiprazole Attenuates Aggression, Suicidality and Substance Use in Borderline Personality Disorder: A Case Series;Medicina;2024-02-07

3. Preclinical evidence for the use of the atypical antipsychotic, brexpiprazole, for opioid use disorder;Neuropharmacology;2023-08

4. Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice;Journal of Psychopharmacology;2023-07-03

5. Synergistic anti‐depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice;Neuropsychopharmacology Reports;2023-01-17